24 research outputs found

    Crawling Water Beetles of Wisconsin (Coleoptera: Haliplidae)

    Get PDF
    (excerpt) Haliplidae are smail water beetles, less than 5 mm long, that frequently occur in abundance in ponds, marshes, sloughs, and swamps and also along the margins of slow streams or lakes where there is not severe wave action. Adults are readily recognized by their yelloa- to orange ground color with black maculations on the elytra and sometimes on the head and pronotum (Figs. 1,3,4). They have a distinctive shape, being broadest at the basss of the elytra and tapered toward the posterior end. The metacoxae are covered by dis~ctive plates that are unique among water beetles (Fig. 2). The tarsi and tibiae of the adults are modified for swimming, and the beetles can swim quite well, although they mostly crawl among the vegetation. Adults and larvae are found among vegetation upon which they feed, filamentous algae being the primary source of food for most species, but detrims and animal material may form a portion of the diet in some species. In Wisconsin most species probably have a one-year life cycle and overwinter as adults. Eggs are laid during spring and early summer, usually in or upon algae. There are three larval instars, and pupation takes place in moist soil above the water line. Larvae have been derrihd for only a few species, so identification is based upon adult characteristics

    Chapter 9: Aquatic Macroinvertebrates, Section A: Aquatic Macroinvertebrates (Exclusive of Mosquitoes)

    Get PDF
    Final Report. Excerpt (Chapter 9, Section A) from The Des Plaines River Wetlands Demonstration Project, Volume II, Baseline Survey, edited by Donald L. Hey and Nancy S. PhilippiReport issued on: October 1985INHS Technical Report prepared for Wetlands Research, Inc

    Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study

    Get PDF
    Background: The impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on postoperative recovery needs to be understood to inform clinical decision making during and after the COVID-19 pandemic. This study reports 30-day mortality and pulmonary complication rates in patients with perioperative SARS-CoV-2 infection. Methods: This international, multicentre, cohort study at 235 hospitals in 24 countries included all patients undergoing surgery who had SARS-CoV-2 infection confirmed within 7 days before or 30 days after surgery. The primary outcome measure was 30-day postoperative mortality and was assessed in all enrolled patients. The main secondary outcome measure was pulmonary complications, defined as pneumonia, acute respiratory distress syndrome, or unexpected postoperative ventilation. Findings: This analysis includes 1128 patients who had surgery between Jan 1 and March 31, 2020, of whom 835 (74·0%) had emergency surgery and 280 (24·8%) had elective surgery. SARS-CoV-2 infection was confirmed preoperatively in 294 (26·1%) patients. 30-day mortality was 23·8% (268 of 1128). Pulmonary complications occurred in 577 (51·2%) of 1128 patients; 30-day mortality in these patients was 38·0% (219 of 577), accounting for 81·7% (219 of 268) of all deaths. In adjusted analyses, 30-day mortality was associated with male sex (odds ratio 1·75 [95% CI 1·28–2·40], p\textless0·0001), age 70 years or older versus younger than 70 years (2·30 [1·65–3·22], p\textless0·0001), American Society of Anesthesiologists grades 3–5 versus grades 1–2 (2·35 [1·57–3·53], p\textless0·0001), malignant versus benign or obstetric diagnosis (1·55 [1·01–2·39], p=0·046), emergency versus elective surgery (1·67 [1·06–2·63], p=0·026), and major versus minor surgery (1·52 [1·01–2·31], p=0·047). Interpretation: Postoperative pulmonary complications occur in half of patients with perioperative SARS-CoV-2 infection and are associated with high mortality. Thresholds for surgery during the COVID-19 pandemic should be higher than during normal practice, particularly in men aged 70 years and older. Consideration should be given for postponing non-urgent procedures and promoting non-operative treatment to delay or avoid the need for surgery. Funding: National Institute for Health Research (NIHR), Association of Coloproctology of Great Britain and Ireland, Bowel and Cancer Research, Bowel Disease Research Foundation, Association of Upper Gastrointestinal Surgeons, British Association of Surgical Oncology, British Gynaecological Cancer Society, European Society of Coloproctology, NIHR Academy, Sarcoma UK, Vascular Society for Great Britain and Ireland, and Yorkshire Cancer Research

    Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

    Get PDF
    Background: Many patients with COVID-19 have been treated with plasma containing anti-SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent plasma therapy in patients admitted to hospital with COVID-19. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]) is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. The trial is underway at 177 NHS hospitals from across the UK. Eligible and consenting patients were randomly assigned (1:1) to receive either usual care alone (usual care group) or usual care plus high-titre convalescent plasma (convalescent plasma group). The primary outcome was 28-day mortality, analysed on an intention-to-treat basis. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936. Findings: Between May 28, 2020, and Jan 15, 2021, 11558 (71%) of 16287 patients enrolled in RECOVERY were eligible to receive convalescent plasma and were assigned to either the convalescent plasma group or the usual care group. There was no significant difference in 28-day mortality between the two groups: 1399 (24%) of 5795 patients in the convalescent plasma group and 1408 (24%) of 5763 patients in the usual care group died within 28 days (rate ratio 1·00, 95% CI 0·93–1·07; p=0·95). The 28-day mortality rate ratio was similar in all prespecified subgroups of patients, including in those patients without detectable SARS-CoV-2 antibodies at randomisation. Allocation to convalescent plasma had no significant effect on the proportion of patients discharged from hospital within 28 days (3832 [66%] patients in the convalescent plasma group vs 3822 [66%] patients in the usual care group; rate ratio 0·99, 95% CI 0·94–1·03; p=0·57). Among those not on invasive mechanical ventilation at randomisation, there was no significant difference in the proportion of patients meeting the composite endpoint of progression to invasive mechanical ventilation or death (1568 [29%] of 5493 patients in the convalescent plasma group vs 1568 [29%] of 5448 patients in the usual care group; rate ratio 0·99, 95% CI 0·93–1·05; p=0·79). Interpretation: In patients hospitalised with COVID-19, high-titre convalescent plasma did not improve survival or other prespecified clinical outcomes. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research

    Survey of Kankakee River Mussels (Mollusca: Unionidae) at Site of Proposed Hydroelectric Plant Reconstruction, City of Kankakee, Kankakee County, Illinois

    Get PDF
    Final Report issued May 17, 1985Report issued on: May 17, 1985INHS Technical Report prepared for City of Kankakee Department of Water Pollution Contro

    A Stress Function for Evaluating Strategies for Water Quality Management

    Get PDF
    R-805614-01-0; issue date unknown, but report includes data gathered in 1976 and most recent publication listed in bibliography is from 1979.Prepared for Municipal Environmental Research Laboratory, Office of Research and Development, U.S. Environmental Protection Agenc

    Sulfur budget of Lake Shelbyville, Illinois, and the Effects of Sulfides upon Chaoborus

    Get PDF
    Research Report No. 66, Final Report, Project No. A-056-ILL, Agreement No. 14-31-0001-3813Report issued on: June 1973Submitted to unknown recipien
    corecore